Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Estrogen Receptor-positive Breast Cancer: early-phase trial registry
6 of 17 indexed Estrogen Receptor-positive Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 6 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Estrogen Receptor-positive Breast Cancer: 17 US clinical trials tracked, 6 recruiting.
Estrogen Receptor-positive Breast Cancer is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is University of Pittsburgh Medical Center, running 1 of these trials.
Enrollment posture brief
Registry condition estrogen-receptor-positive-breast-cancer
OPEN 6 | RECR 35% | LATE 2 | EARLY 8 | RANK #1004 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Arrhythmia (35% recruiting · 17 trials)
Estrogen Receptor-positive Breast Cancer lists 6 open slots (35% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Estrogen Receptor-positive Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Estrogen Receptor-positive Breast Cancer is recruiting below its size-band peers.
6 of 17 indexed trials (35.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Estrogen Receptor-positive Breast Cancer trials is spread across many organizations.
University of Pittsburgh Medical Center accounts for 1 of 17 trials (5.9%). 17 distinct sponsors appear on at least one study for this condition label.
-
Most Estrogen Receptor-positive Breast Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 72 among the 17 trials that report a genuine target (sentinel values excluded). 11 of those (64.7%) plan for fewer than 100 participants.
-
Estrogen Receptor-positive Breast Cancer research is mostly interventional.
14 interventional and 3 observational studies make up this index (82.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT07222215
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
NCT06062498
Breast Re-irradiation After Second Ipsilateral Lumpectomy
Youssef Zeidan
NCT06867484
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Atossa Therapeutics
NCT05607004
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
NCT06439693
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
Mayo Clinic
NCT06525766
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology
NCT01953588
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ECOG-ACRIN Cancer Research Group
NCT01824836
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
Alliance Foundation Trials
NCT02947685
FDG PET/CT in Breast Cancer Bone Mets
University of Pennsylvania
NCT01996046
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
NCT01791478
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
NCT02957968
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
Polly A. Niravath, MD
NCT01984138
Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer
Duke University
NCT03719495
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
City of Hope Medical Center
NCT02235051
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
University of Arizona
NCT01385280
Electronic Medical Record-Based Nudge to Reduce SLNB
University of Pittsburgh Medical Center
NCT06006910
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Estrogen Receptor-positive Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Estrogen Receptor-positive Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Estrogen Receptor-positive Breast Cancer page
17 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Estrogen Receptor-positive Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Pittsburgh Medical Center sponsors the most Estrogen Receptor-positive Breast Cancer trials on record, review their full trial history before evaluating a specific study. See University of Pittsburgh Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Estrogen Receptor-positive Breast Cancer condition card totals 17 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.